Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

By Brian J. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones and 1 more. New England Journal of Medicine, 2001

5,221 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Rheumatology

View Paper: https://www.semanticscholar.org/paper/1abb4b6b3dcdf06bbd6761e3509c9d23645aa487

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Brian J. Druker
2. K. Borden
3. H. Zahreddine
4. Christine Lovly
5. Z. Du
6. J. Melo
7. F. S. Collins
8. Adi F. Gazdar

In Molecular Biology

1. Guido Kroemer
2. Beth Levine
3. L. Galluzzi
4. Arul M. Chinnaiyan
5. Eric S. Lander
6. Heng Li
7. Paul Flicek
8. Dina Demner-Fushman

In Rheumatology

1. Brian J. Druker
2. Michael R. Stratton
3. K. Borden
4. H. Zahreddine
5. J. Cortes
6. Andreas Hochhaus
7. J. O’Shea
8. Z. Du

Citations in the corpus

• Chemotherapy and the war on cancer (2005, background): “However, BCR–ABL translocation can still be detected by PCR analysis in cells of most patient”
• The Connectivity Map: a new tool for biomedical research (2007, neutral): “) to rationality (chronic myeloid leukaemia–BCR-ABL–imatini”
• Lessons from the cancer genome. (2013, neutral): “The poster child was imatinib (Gleevec) against the ABL and KIT kinases, which proved remarkably effective in treating malignancies driven by activating mutations in these oncoproteins (chronic myelogenous leukemia [CML] and gastrointestinal stromal tumors [GIST]) (Demetri et al., 2002; Druker et al”
• Autophagy in malignant transformation and cancer progression (2015, positive): “BCR-ABL1 is a constitutively active kinase and is etiologically involved in leukemogenesis, as demonstrated by the outstanding clinical success of imatinib mesylate, a BCR-ABL1-targeting kinase inhibitor (Druker et al , 2001).”
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. (2010, background): “Some CML-CP and most dvanced phase patients relapsed after months or years of treatent with imatinib due to the development of resistance (this will e discussed further in the later section of this review) [38,39].”
• The hunting of the Src. (2001, background): “, and that an abl inhibitor is effective in the treatment of chronic myelogenous leukaemi”
• Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002, neutral): “Median age, y (range) 56 (19-81) 57 (19-81) 52 (20-73) 56 (19-81)”
• Protein kinases — the major drug targets of the twenty-first century? (2002, background): “After the initiation of a clinical trial, spectacular efficacy and minimal side effects were show”